{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:29:13Z","timestamp":1787765353179,"version":"build-2784847793"},"reference-count":116,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Minister of Science and Higher Education","award":["002\/RID\/2018\/19"],"award-info":[{"award-number":["002\/RID\/2018\/19"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bortezomib (BTZ) is widely implemented in the treatment of multiple myeloma (MM). Its main mechanism of action is very well established. BTZ selectively and reversibly inhibits the 26S proteasome. More precisely, it interacts with the chymotryptic site of the 20S proteasome and therefore inhibits the degradation of proteins. This results in the intracellular accumulation of misfolded or otherwise defective proteins leading to growth inhibition and apoptosis. As well as interfering with the ubiquitin\u2013proteasome complex, BTZ elicits various epigenetic alterations which contribute to its cytotoxic effects as well as to the development of BTZ resistance. In this review, we summarized the epigenetic alterations elicited by BTZ. We focused on modifications contributing to the mechanism of action, those mediating drug-resistance development, and epigenetic changes promoting the occurrence of peripheral neuropathy. In addition, there are therapeutic strategies which are specifically designed to target epigenetic changes. Herein, we also reviewed epigenetic agents which might enhance BTZ-related cytotoxicity or restore the sensitivity to BTZ of resistant clones. Finally, we highlighted putative future perspectives regarding the role of targeting epigenetic changes in patients exposed to BTZ.<\/jats:p>","DOI":"10.3390\/cancers16010084","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T20:49:27Z","timestamp":1703450967000},"page":"84","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8695-8863","authenticated-orcid":false,"given":"Piotr","family":"Kulig","sequence":"first","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4008-7473","authenticated-orcid":false,"given":"Karolina","family":"\u0141uczkowska","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estera","family":"Bakinowska","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9933-5844","authenticated-orcid":false,"given":"Bart\u0142omiej","family":"Baumert","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Pomeranian Medical University, 71-252 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Machali\u0144ski","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"},{"name":"Department of Hematology and Transplantology, Pomeranian Medical University, 71-252 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/mr.56.2.291-315.1992","article-title":"Mechanism and regulation of eukaryotic protein synthesis","volume":"56","author":"Merrick","year":"1992","journal-title":"Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: Mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduc. Target Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/emboj\/19.1.94","article-title":"Recognition of the polyubiquitin proteolytic signal","volume":"19","author":"Thrower","year":"2000","journal-title":"EMBO J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0962-8924(98)01491-3","article-title":"Gettin\u2019 down with ubiquitin: Turning off cell-surface receptors, transporters and channels","volume":"9","author":"Hicke","year":"1999","journal-title":"Trends Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6705927","DOI":"10.1155\/2016\/6705927","article-title":"The Importance of Ubiquitination and Deubiquitination in Cellular Reprogramming","volume":"2016","author":"Suresh","year":"2016","journal-title":"Stem Cells Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.jmb.2017.05.027","article-title":"Proteasome Structure and Assembly","volume":"429","author":"Budenholzer","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and Function of the 26S Proteasom","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"204062072110196","DOI":"10.1177\/20406207211019612","article-title":"The role of carfilzomib in relapsed\/refractory multiple myeloma","volume":"12","author":"Yee","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/14740338.2017.1344212","article-title":"Safety of ixazomib for the treatment of multiple myeloma","volume":"16","author":"Bonnet","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_11","first-page":"273","article-title":"Clinical pharmacokinetics of bortezomib","volume":"21","author":"Carvalho","year":"2007","journal-title":"In Vivo"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/DDDT.S93602","article-title":"Spotlight on ixazomib: Potential in the treatment of multiple myeloma","volume":"2016","author":"Azab","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_13","first-page":"303","article-title":"Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed and\/or Refractory Multiple Myeloma","volume":"41","author":"Perel","year":"2016","journal-title":"P T Peer-Rev. J. Formul. Manag."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/14737140.2016.1123627","article-title":"Oral ixazomib maintenance therapy in multiple myeloma","volume":"16","author":"Offidani","year":"2016","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","article-title":"Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy","volume":"57","author":"Richardson","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1200\/JCO.2005.01.136","article-title":"Proteasome Inhibition with Bortezomib (PS-341): A Phase I Study with Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycl","volume":"23","author":"Hamilton","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.105.005710","article-title":"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib","volume":"33","author":"Uttamsingh","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1021\/tx050313d","article-title":"Oxidative Deboronation of the Peptide Boronic Acid Proteasome Inhibitor Bortezomib: Contributions from Reactive Oxygen Species in This Novel Cytochrome P450 Reactio","volume":"19","author":"Labutti","year":"2006","journal-title":"Chem. Res. Toxicol."},{"key":"ref_20","first-page":"14","article-title":"Pharmacology, pharmacokinetics, and practical applications of bortezomib","volume":"18","author":"Schwartz","year":"2004","journal-title":"Oncology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/cncr.21427","article-title":"Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma","volume":"104","author":"Berenson","year":"2005","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3346\/jkms.2005.20.4.598","article-title":"A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma","volume":"20","author":"Lee","year":"2005","journal-title":"J. Korean Med. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","article-title":"Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2011.09.006","article-title":"Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer","volume":"76","author":"Besse","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","article-title":"Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma","volume":"115","author":"Taetle","year":"2010","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1179\/1607845414Y.0000000218","article-title":"Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study","volume":"20","author":"Oriol","year":"2015","journal-title":"Hematology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000322866","article-title":"Bortezomib Retreatment in Relapsed Multiple Myeloma\u2014Results from a Retrospective Multicentre Survey in Germany and Switzerland","volume":"79","author":"Hrusovsky","year":"2010","journal-title":"Oncology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1002\/hsr2.104","article-title":"Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice","volume":"2","author":"Hulin","year":"2019","journal-title":"Health Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.21517","article-title":"Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib","volume":"84","author":"Sood","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children\u2019s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3816\/CBC.2010.n.061","article-title":"Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer","volume":"10","author":"Irvin","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"ref_36","first-page":"657","article-title":"A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer","volume":"27","author":"Trinh","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.21873\/invivo.12917","article-title":"A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients with BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044\/EBLIN)","volume":"36","author":"Lee","year":"2022","journal-title":"Vivo"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3816\/CLC.2011.n.004","article-title":"Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: A California cancer consortium trial","volume":"12","author":"Lara","year":"2011","journal-title":"Clin. Lung Cancer"},{"key":"ref_39","first-page":"135","article-title":"Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000323874","article-title":"Epigenetics: Principles and Practice","volume":"29","author":"Hamilton","year":"2011","journal-title":"Dig. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Metere, A., and Graves, C.E. (2020). Factors Influencing Epigenetic Mechanisms: Is There A Role for Bariatric Surgery?. High-Throughput, 9.","DOI":"10.3390\/ht9010006"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41392-023-01333-7","article-title":"Epigenetic regulation in metabolic diseases: Mechanisms and advances in clinical study","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9846","DOI":"10.1038\/s41598-021-89128-0","article-title":"Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound","volume":"11","author":"Sokolowska","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"\u0141uczkowska, K., Taryma-Le\u015bniak, O., Bi\u0144kowski, J., Soko\u0142owska, K.E., Strapagiel, D., Jarczak, J., Paczkowska, E., Machali\u0144ski, B., and Wojdacz, T.K. (2022). Long-Term Treatment with Bortezomib Induces Specific Methylation Changes in Differentiated Neuronal Cells. Cancers, 14.","DOI":"10.3390\/cancers14143402"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"\u0141uczkowska, K., Kulig, P., Rusi\u0144ska, K., Baumert, B., and Machali\u0144ski, B. (2023). 5-Aza-2\u2032-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316780"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"\u0141uczkowska, K., Kulig, P., Baumert, B., and Machali\u0144ski, B. (2022). The Evidence That 25(OH)D3 and VK2 MK-7 Vitamins Influence the Proliferative Potential and Gene Expression Profiles of Multiple Myeloma Cells and the Development of Resistance to Bortezomib. Nutrients, 14.","DOI":"10.3390\/nu14235190"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2007-08-110171","article-title":"Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1\/NF-\u03baB\u2013dependent DNA methyltransferase activity in acute myeloid leukemia","volume":"111","author":"Liu","year":"2008","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"27332","DOI":"10.18632\/oncotarget.2903","article-title":"Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma","volume":"6","author":"Leshchenko","year":"2015","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10433","DOI":"10.1093\/nar\/gku763","article-title":"MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib","volume":"42","author":"Wirth","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood-2009-07-235663","article-title":"Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma","volume":"116","author":"Kikuchi","year":"2010","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Jeusset, L., and McManus, K. (2019). Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer. Cells, 8.","DOI":"10.3390\/cells8020165"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41467-023-36370-x","article-title":"Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia","volume":"14","author":"Kamens","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/1535-7163.1263.3.10","article-title":"Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor","volume":"3","author":"Xu","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1073\/pnas.1619067114","article-title":"Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers","volume":"114","author":"Tsvetkov","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hu, X., Xuan, H., Du, H., Jiang, H., and Huang, J. (2014). Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma. Agoulnik IU, editoPLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095765"},{"key":"ref_56","first-page":"5023","article-title":"Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment","volume":"19","author":"Biassi","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"eaan0941","DOI":"10.1126\/scitranslmed.aan0941","article-title":"Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)","volume":"10","author":"Rashid","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.omto.2020.10.004","article-title":"Methylation of the Promoter Region of the Tight Junction Protein-1 by DNMT1 Induces EMT-like Features in Multiple Myeloma","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Qi, W., White, M.C., Choi, W., Guo, C., Dinney, C., McConkey, D.J., and Siefker-Radtke, A. (2013). Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069509"},{"key":"ref_60","first-page":"729","article-title":"Synergistic Efficacy of the Demethylation Agent Decitabine in Combination with the Protease Inhibitor Bortezomib for Treating Multiple Myeloma through the Wnt\/\u03b2-Catenin Pathway","volume":"27","author":"Jin","year":"2019","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2016.96","article-title":"A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells","volume":"30","author":"Das","year":"2016","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3892\/mmr.2016.5658","article-title":"Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells","volume":"14","author":"Cao","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.ymthe.2021.12.012","article-title":"FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner","volume":"30","author":"Xu","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41419-023-06036-z","article-title":"PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6","volume":"14","author":"Jia","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sun, X., Xie, Y., Sun, X., Yao, Y., Li, H., Li, Z., Yao, Y., and Xu, K. (2019). The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma. Biosci. Rep., 39.","DOI":"10.1042\/BSR20181916"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: Association with disease characteristics and treatment responsE","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12185-020-03005-6","article-title":"Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents","volume":"113","author":"Sato","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1002\/ctm2.744","article-title":"Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma","volume":"12","author":"Jiang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41467-021-21386-y","article-title":"Targeting NSD2-mediated SRC-3 liquid\u2013liquid phase separation sensitizes bortezomib treatment in multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Bollmann, L.M., Skerhut, A.J., Asfaha, Y., Horstick, N., Hanenberg, H., Hamacher, A., Kurz, T., and Kassack, M.U. (2022). The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113398"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41419-020-2414-3","article-title":"Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib","volume":"11","author":"Xu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41408-017-0001-3","article-title":"Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells","volume":"7","author":"Muguruma","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000357213","article-title":"Romidepsin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma Cells","volume":"132","author":"Sripayap","year":"2014","journal-title":"Acta Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e3167","DOI":"10.1038\/cddis.2017.520","article-title":"Bortezomib-induced miRNAs direct epigenetic silencing of locus genes and trigger apoptosis in leukemia","volume":"8","author":"Chu","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1080\/15384101.2020.1839701","article-title":"Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p\/JAG1 axis","volume":"19","author":"Wang","year":"2020","journal-title":"Cell Cycle"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.18632\/oncotarget.675","article-title":"DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma","volume":"3","author":"Amodio","year":"2012","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.4161\/cc.26585","article-title":"miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells","volume":"12","author":"Amodio","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1038\/cddis.2012.175","article-title":"miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1","volume":"3","author":"Amodio","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cca.2018.02.019","article-title":"Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma","volume":"480","author":"Pan","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41419-018-1219-0","article-title":"LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p","volume":"10","author":"Pan","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41419-019-1551-z","article-title":"Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b","volume":"10","author":"Fu","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2016.325","article-title":"Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma","volume":"31","author":"Qin","year":"2017","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/15548627.2019.1635380","article-title":"MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4","volume":"16","author":"Wu","year":"2020","journal-title":"Autophagy"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.bbrc.2019.05.078","article-title":"Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression","volume":"514","author":"Nian","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/CAD.0000000000001166","article-title":"Circular RNA circ-CCT3 promotes bortezomib resistance in multiple myeloma via modulating miR-223-3p\/BRD4 axis","volume":"33","author":"Liu","year":"2022","journal-title":"Anti-Cancer Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.5852","article-title":"Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs","volume":"256","author":"Saltarella","year":"2022","journal-title":"J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/15384101.2019.1632138","article-title":"miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1","volume":"18","author":"Yuan","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4149\/neo_2021_210205N184","article-title":"LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN","volume":"68","author":"Yang","year":"2021","journal-title":"Neoplasma"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"173752","DOI":"10.1016\/j.ejphar.2020.173752","article-title":"Lnc NEAT1\/miR-29b-3p\/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells","volume":"891","author":"Che","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/CAD.0000000000001378","article-title":"Circ_0005615 contributes to the progression and Bortezomib resistance of multiple myeloma by sponging miR-185-5p and upregulating IRF4","volume":"33","author":"Fu","year":"2022","journal-title":"Anti-Cancer Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcb.29684","article-title":"miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28","volume":"122","author":"Chen","year":"2021","journal-title":"J. Cell. Biochem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cbin.11540","article-title":"Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib","volume":"45","author":"Tang","year":"2021","journal-title":"Cell Biol. Int."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Malek, E., Kim, B., and Driscoll, J. (2016). Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors. Genes, 7.","DOI":"10.3390\/genes7100084"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.7150\/jca.35098","article-title":"Knockdown of long non-coding RNA PCAT-1 inhibits myeloma cell growth and drug resistance via p38 and JNK MAPK pathways","volume":"10","author":"Shen","year":"2019","journal-title":"J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"106785","DOI":"10.1016\/j.leukres.2022.106785","article-title":"MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner","volume":"114","author":"Liu","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3892\/or.2016.5318","article-title":"hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10","volume":"37","author":"Xi","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_98","first-page":"1058","article-title":"MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2","volume":"43","author":"Tian","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3324\/haematol.2019.227579","article-title":"Targeting CD47\/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma","volume":"105","author":"Rastgoo","year":"2019","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Lerner, M., Haneklaus, M., Harada, M., and Grand\u00e9r, D. (2012). MiR-200c Regulates Noxa Expression and Sensitivity to Proteasomal Inhibitors. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036490"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"106967","DOI":"10.1016\/j.leukres.2022.106967","article-title":"LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma","volume":"123","author":"Zang","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/leu.2014.279","article-title":"MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib","volume":"29","author":"Jagannathan","year":"2015","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"\u0141uczkowska, K., Rogi\u0144ska, D., Kulig, P., Bielikowicz, A., Baumert, B., and Machali\u0144ski, B. (2022). Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052431"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"174480691986329","DOI":"10.1177\/1744806919863292","article-title":"GATA3-dependent epigenetic upregulation of CCL21 is involved in the development of neuropathic pain induced by bortezomib","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Pain"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12974-018-1327-x","article-title":"Reduction of SIRT1 epigenetically upregulates NALP1 expression and contributes to neuropathic pain induced by chemotherapeutic drug bortezomib","volume":"15","author":"Chen","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.expneurol.2018.01.011","article-title":"Upregulation of NLRP3 via STAT3-dependent histone acetylation contributes to painful neuropathy induced by bortezomib","volume":"302","author":"Liu","year":"2018","journal-title":"Exp. Neurol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Rullo, L., Franchi, S., Amodeo, G., Caputi, F.F., Verduci, B., Losapio, L.M., Sacerdote, P., Romualdi, P., and Candeletti, S. (2021). Interplay between Prokineticins and Histone Demethylase KDM6A in a Murine Model of Bortezomib-Induced Neuropathy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111913"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1007\/s11064-022-03571-7","article-title":"Metformin Relieves Bortezomib-Induced Neuropathic Pain by Regulating AMPKa2-Mediated Autophagy in the Spinal Dorsal Horn","volume":"47","author":"Liu","year":"2022","journal-title":"Neurochem. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1080\/10428194.2021.1933478","article-title":"microRNAs as the biomarkers of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma","volume":"62","author":"Safranow","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"\u0141uczkowska, K., Rutka, M., Rogi\u0144ska, D., Paczkowska, E., Baumert, B., Milczarek, S., G\u00f3rska, M., Kulig, P., Os\u0119kowska, B., and Janowski, M. (2021). The Potential Role of Proinflammatory Cytokines and Complement Components in the Development of Drug-Induced Neuropathy in Patients with Multiple Myeloma. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194584"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.leukres.2013.01.013","article-title":"Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib","volume":"37","author":"Cibeira","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Szudy-Szczyrek, A., Mlak, R., Mielnik, M., Mazurek, M., Chocholska, S., Podgajna, M., Szczyrek, M., Homa-Mlak, I., Ma\u0142ecka-Massalska, T., and Hus, M. (2022). Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. Cells, 11.","DOI":"10.3390\/cells11040752"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1007\/s12325-016-0413-7","article-title":"The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective","volume":"33","author":"Einsele","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"Hungria","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.0c02255","article-title":"Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma","volume":"64","author":"Rabal","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/84\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:40:56Z","timestamp":1760132456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,23]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16010084"],"URL":"https:\/\/doi.org\/10.3390\/cancers16010084","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,23]]}}}